HENGRUI PHARMA Subsidiary Receives NMPA Approval for HRS-1635 Tablets Clinical Trial

Stock News

05/26

HENGRUI PHARMA (600276.SH) announced that its subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., has recently received a Drug Clinical Trial Approval Notice for HRS-1635 tablets from the National Medical Products Administration (NMPA). Clinical trials for the drug are scheduled to commence in the near future.

HRS-1635 tablets are an innovative anti-tumor drug independently developed by the company, intended for the treatment of B-cell malignancies. According to available information, there are currently no similar drugs approved for marketing either domestically or internationally.

As of now, the cumulative research and development investment for the HRS-1635 tablets project amounts to approximately 23.6 million yuan (unaudited).

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1122795185"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122795185\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122795185?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 16:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122795185","market":"other","top_or_hot":-1,"title":"HENGRUI PHARMA Subsidiary Receives NMPA Approval for HRS-1635 Tablets Clinical Trial","media":"Stock News","content":"<p>HENGRUI PHARMA (600276.SH) announced that its subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., has recently received a Drug Clinical Trial Approval Notice for HRS-1635 tablets from the National Medical Products Administration (NMPA). Clinical trials for the drug are scheduled to commence in the near future.</p>\n<p>HRS-1635 tablets are an innovative anti-tumor drug independently developed by the company, intended for the treatment of B-cell malignancies. According to available information, there are currently no similar drugs approved for marketing either domestically or internationally.</p>\n<p>As of now, the cumulative research and development investment for the HRS-1635 tablets project amounts to approximately 23.6 million yuan (unaudited).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENGRUI PHARMA Subsidiary Receives NMPA Approval for HRS-1635 Tablets Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENGRUI PHARMA Subsidiary Receives NMPA Approval for HRS-1635 Tablets Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-26 16:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENGRUI PHARMA (600276.SH) announced that its subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., has recently received a Drug Clinical Trial Approval Notice for HRS-1635 tablets from the National Medical Products Administration (NMPA). Clinical trials for the drug are scheduled to commence in the near future.</p>\n<p>HRS-1635 tablets are an innovative anti-tumor drug independently developed by the company, intended for the treatment of B-cell malignancies. According to available information, there are currently no similar drugs approved for marketing either domestically or internationally.</p>\n<p>As of now, the cumulative research and development investment for the HRS-1635 tablets project amounts to approximately 23.6 million yuan (unaudited).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1023057109.AUD","symbol_name":"BGF CHINA \"A2\" (AUDHDG) ACC","start_time":0,"source_url":"","article_id":"1122795185","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122795185","pubTimestamp":1779785665,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENGRUI PHARMA (600276.SH) announced that its subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., has recently received a Drug Clinical Trial Approval Notice for HRS-1635 tablets from the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0196":"行业龙头","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","BK0239":"医药制造","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","01276":"恒瑞医药","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK0183":"MSCI概念","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0188":"融资融券","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK0012":"证金概念","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0028":"国家队","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK1191":"制药","BK0060":"抗癌","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU0359201612.USD":"贝莱德中国基金A2"},"translate_title":"恒瑞医药子公司HRS-1635片临床试验获NMPA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"01276":1},"content_text":"HENGRUI PHARMA (600276.SH) announced that its subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., has recently received a Drug Clinical Trial Approval Notice for HRS-1635 tablets from the National Medical Products Administration (NMPA). Clinical trials for the drug are scheduled to commence in the near future.\nHRS-1635 tablets are an innovative anti-tumor drug independently developed by the company, intended for the treatment of B-cell malignancies. According to available information, there are currently no similar drugs approved for marketing either domestically or internationally.\nAs of now, the cumulative research and development investment for the HRS-1635 tablets project amounts to approximately 23.6 million yuan (unaudited).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}